Forbes covers a World Health Organization warning against GLP-1 weight loss drugs for kids and explains the reasoning behind it.
Recap by typeshit. Full story at Forbes.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
In survey data presented at EADV 2026, 39% of GLP-1 users reported nails lifting versus 9% of nonusers. The lead author says overall health likely explains much of the gap.
Researchers reviewed records of nearly a million diabetic patients and found a 40% to 70% lower rate of first Alzheimer's diagnosis. Lead author Rong Xu says it's a link, not proof. Story dates from 2024.
Loading…